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G protein-coupled receptors (GPCRs) comprise a large family of membrane receptors
involved in signal transduction. These receptors are linked to a variety of physiological
and biological processes such as regulation of neurotransmission, growth, and cell
differentiation among others. Some of the effects of GPCRs are known to be mediated
by the activation of mitogen-activated extracellular kinase (MAPK) pathways. Cross-talk
among various signal pathways plays an important role in activation of intracellular and
intranuclear signal transduction cascades. Naloxone-induced morphine withdrawal leads
to an up-regulation of adenyl cyclase-mediated signaling, resulting in high expression of
protein kinase (PK) A. In addition, there is also an increased expression of extracellular
signal regulated kinase (ERK), one member of MAPK. For this reason, the crosstalk
between these GPCRs and receptors with tyrosine kinase activity (TKR) can be considered
a possible mechanism for adaptive changes that occurs after morphine withdrawal.
Morphine withdrawal activates ERK1/2 and phosphorylated tyrosine hydroxylase (TH) at
Ser31 in the right and left ventricle. When N-(2-guanidinoethyl)-5-isoquinolinesulfonamide
(HA-1004), a PKA inhibitor was infused, the ability of morphine withdrawal to activate ERK,
which phosphorylates TH at Ser31, was reduced. The present finding demonstrated that
the enhancement of ERK1/2 expression and the phosphorylation state of TH at Ser31
during morphine withdrawal are dependent on PKA and suggest cross-talk between PKA
and ERK1/2 transduction pathway mediating morphine withdrawal-induced activation of
TH. Increasing understanding of the mechanisms that interconnect the two pathway
regulated by GPCRs and TKRs may facilitate the design of new therapeutic strategies.
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INTRODUCTION
The development of opioid addiction involves complex adap-
tive changes in opioid receptors and associated signaling systems
leading to neuronal plasticity in specific brain regions (Nestler
and Aghajanian, 1997; Ueda, 2004). In addition to the neu-
robehavioral consequences of opioid addiction, there is a strong
association between drug addiction and cardiac disorders. There
are studies in the literature supporting mainly the effect of
cocaine abuse (Aquaro et al., 2011; Basso et al., 2011) but less
in heroin abuse. However, various types of cardiac arrhythmias
have been described in heroin addicts. Moreover, street heroin
addicts frequently die suddenly, and there is evidence that this
is an arrhythmia-related event (Nerantzis et al., 2011). Despite
the clinical relevance of an association between addiction and
cardiovascular disorders, little is known about the pathophysiol-
ogy or mechanisms underlying this comorbidity. The majority
of cardiology studies were oriented on clinical usage of this
drug and current cardiovascular research has been limited to the
evaluation of factors or pathways believed to contribute to its
physiological actions (Jiang et al., 2006; Xu et al., 2011). So, inves-
tigation about the mechanisms implicated in the cardiac adaptive
changes that occur during morphine withdrawal deserves more
attention.
Although the μ opioid receptor is negatively coupled to the
adenylate cyclase/cAMP-dependent protein kinase (PK) A path-
way upon acute stimulation (Childers, 1991), the pathway is
up-regulated in cardiac tissues after chronic morphine treat-
ment (Milanés et al., 1999). Furthermore, it has been demon-
strated that PKA plays an important role in regulating protein
phosphorylation and contraction in cardiac muscle [see Sugden
and Bogoyevitch (1995) for review]. Cardiac inotropic activ-
ity is strongly regulated by intracellular PKA (Hussain et al.,
1999; Kamp and Hell, 2000). Previous studies in our laboratory
have demonstrated that naloxone administration to morphine-
dependent rats leads to an increase in the force and rate of con-
traction in different cardiac tissues (Rabadán et al., 1997, 1998).
In addition, it has been demonstrated that withdrawal from mor-
phine is associated with a marked increase in the ventricular levels
of cAMP in parallel with an enhancement of noradrenaline (NA)
turnover (Milanés et al., 2000).
Extracellular signal-regulated kinase (ERK), one mem-
ber of mitogen-activated extracellular kinase (MAPK) family,
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transduces a broad range of extracellular stimuli into diverse
intracellular responses. ERK signaling pathway could be impor-
tant as regulator of cardiac function [see Michel et al. (2001) for
review]. Recently, several studies have shown that this pathway
contributes to naloxone-precipitated withdrawal in morphine
dependent rats (Ren et al., 2004; Almela et al., 2007a, 2008).
It is now appreciated that crosstalk among various signal path-
ways plays an important role in activation of intracellular and
intranuclear signal transduction cascades. Different studies have
shown a crosstalk between cAMP and MAPK (see Stork and
Schmitt, 2002, for reviews). cAMP stimulates MAPK activity in
cultured neurons (Villalba et al., 1997; Vossler et al., 1997) and
is required for its nuclear translocation (Impey et al., 1998).
Crosstalk between cAMP/PKA and MAPK pathways is neces-
sary to regulate genetic expression (Sengupta et al., 2007). It
has been demonstrated that PKA, MAPK, and mitogen- and
stress-activated protein kinase (MSK1) are activated in the same
subset of CA1 pyramidal neurons, and that Ca2+-stimulated
adenyl cyclase activity is indispensable for the training-induced
activation of MAPK, MSK1, and CREB (cAMP response ele-
ment binding protein) (Sindreu et al., 2007). Above mentioned
studies showed that G protein-coupled receptors (GPCRs) and
receptors with tyrosine kinase activity (TKR) represent distinct
and linear signaling units that converge on down-stream targets.
Therefore, the increase in PKA activity may be necessary to sup-
port the activation of MAPK during morphine withdrawal in
the heart. However, there is no evidence that PKA activation is
required for stimulation of ERKs and subsequently phosphoryla-
tion of TH at Ser 31 in morphine-dependent rats. The present
study examine whether the interaction between PKA and ERK
signaling pathways, in the heart, mediates the enhancement of
TH phosphorylation observed after naloxone administration to
morphine-dependent rats.
METHODS
Male Sprague-Dawley rats (220–240 g at the beginning of the
experiments) were housed four-to-five per cage under a 12-h
light/dark cycle (light: 8:00–20:00 h) in a room with controlled
temperature (22 ± 2◦C), humidity (50 ± 10%), food and water
available ad libitum and handled for several days preceding the
experiment to minimize stress, as previously described (Laorden
et al., 2000). All surgical and experimental procedures were per-
formed in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) and the local
Committee.
EXPERIMENTAL PROCEDURE
Rats were rendered tolerant/dependent on morphine by s.c.
implantation of morphine base pellets (75mg), one on day 1,
two on day 3, and three on day 5, under light ether anaesthe-
sia (Rabadán et al., 1997; Milanés et al., 2000). Control animals
were implanted with placebo pellets containing lactose instead of
morphine, on the same time schedule. This procedure has been
shown to produce consistent plasma morphine concentrations
beginning a few hours after the implantation of the pellets and
a full withdrawal syndrome after acute injection of opioids antag-
onist (Frenois et al., 2002). Dependence on morphine remained
FIGURE 1 | (A) Effect or morphine pellet-implantation on body weight gain.
(B) Body weight loss after naloxone-precipitated withdrawal. Animals
received subcutaneous implantation of placebo or morphine pellets for 7
days. On day 8, rats were injected with saline or naloxone (nx, 2mg/kg) and
decapitated 60min later. (C)Other groups of animals were pretreated with
vehicle (veh), HA-1004 (HA, 40 nmol/day), calphostin C (CA, 40 pmol/day) or
SL-327 (SL, 100mg/kg i.p.). Data are the mean ± s.e.m. çççp < 0.001 vs.
placebo; ∗∗∗p < 0.001 vs. morphine-dependent group receiving saline
instead of naloxone; +++p < 0.001 vs. the control group injected with
naloxone; ###p < 0.001 vs. placebo+HA+nx; &&&p < 0.01 vs.
placebo+CA+nx; $$$p < 0.001 vs. placebo+SL+nx.
constant for 15 days (Gold et al., 1994). On day 8, the animals
treated with morphine or placebo pellets were injected with saline
s.c. or naloxone (2mg/kg s.c.). We used this model because the
adaptive changes observed in the heart are more evident after
naloxone-precipitated withdrawal than after deprivation from
morphine.
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The weight gain of the rats was checked along the treatment
to ensure that the morphine was liberated correctly from the
pellets because it is known that chronic morphine treatment
induces a decrease in body weight gain due to lower caloric
intake. In addition, body weight loss was determined as the dif-
ference between the weight checked immediately before saline
or naloxone injection and a second determination made 60min
later.
In order to determine the effects of PKA and PKC on the
morphine withdrawal-induced changes in ERK1/2, animals were
continuously infused for 7 days, via s.c. osmotic minipumps
(Alzet mod. 2001, which deliver at 1μL/h; Alza, Palo Alto, CA,
USA), with HA-1004, a PKA selective inhibitor (Hidaka et al.,
1984) (40 nmol/day), calphostin C, a PKC selective inhibitor
(Kobayashi et al., 1989) (40 pmol/day), or vehicle. PKA inhibitor
was dissolved in sterile water and PKC inhibitor in dymethyl-
sulphoxide (DMSO) and serially diluted in MiIliQ-water (final
concentration of DMSOwas 0.06%). Minipumps were implanted
simultaneously with the chronic morphine or placebo pellets.
Pumps were primed for 5 h before implantation at 37◦C in sterile
saline in order to obtain an optimal flow rate (1μL/h). On day
8, morphine withdrawal syndrome was induced by s.c. naloxone
(2mg/kg) injection. To determine the role of ERK in TH phos-
phorylation in the heart, TH phosphorylated at Ser31 levels were
determined in morphine dependent and control rats treated, 1 h
before the injection of naloxone or saline, with SL327, a selec-
tive inhibitor of mitogen-activated protein kinase (MAPK)/ERK
kinase (MEK) (Atkins et al., 1998). This inhibitor was dissolved
in DMSO (100%) and injected intraperitoneally at an injection
volume of 1ml/kg at dose of 100mg/kg (Almela et al., 2007a).
Other groups of rats were treated with HA-1004 to determine the
role of PKA in ERK and TH phosphorylation.
Animals were killed by decapitation 60 or 90min after nalox-
one or saline administration in order to analyze ERKs and TH
FIGURE 2 | Inmunoblots of PKA (A) and PKCδ (B) in right ventricle
from placebo (pla, p)- or morphine (mor, m)-dependent rats after
naloxone-precipitated withdrawal in vehicle (veh, v)-infused rats and
in animals chronically administered with HA-1004 (HA) or
Calphostin C (CA). Animals received subcutaneous implantation of
placebo or morphine (75mg) pellets for 7 days and concomitantly were
infused with vehicle, HA or CA. On day 8, rats were decapitated
90min after naloxone (nx, n.) administration in presence of vehicle, HA,
CA or SL327 (SL) (C). SL was administered 1 h before naloxone
injection. The immunoreactivity corresponding to PKA or PKCδ is
expressed as a percentage respect to the control group (pla+veh+nx;
defined as 100% value). Data are the mean ± s.e.m. (n = 4–5).
∗∗∗p < 0.001 vs. pla+veh+nx or pla+SL+nx; +++p < 0.001 vs. the group
treated with mor+HA+nx or mor+CA+nx; &p < 0.05, &&p < 0.01 vs.
pla+veh+nx. Bottom panels: representative bands from autoradiograms
at the known apparent molecular weight for PKA and PKCδ.
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phosphorylation. The hearts were rapidly removed, and the right
and left ventricle were dissected, fresh-frozen, and stored imme-
diately at −80◦C until use.
WESTERN BLOT ANALYSIS
Samples were placed in homogenization buffer phosphate
buffered saline, 2% sodium dodecylsulfate (SDS) plus protease
(Boehringer Mannhein, Germany) and phosphatase inhibitor
Cocktail Set (Calbiochem, Germany), and homogenized for 50 s
prior to centrifugation at 6000 g for 20min at 4◦C. Total protein
concentrations were determined spectrophotometrically using
the bicinchoninic acid method (Wiechelman et al., 1988). The
optimal amount of protein to be loaded was determined in
preliminary experiments by loading gels with increasing pro-
tein contents (25–100μg) from samples of each experimental
group. Equal amounts of protein (50μg/lane) from each sam-
ple were loaded on a 10% SDS-polyacrilamide gel (SDS-PAGE),
electrophoresed, and transferred onto poly vinylidene difluo-
ride (PVDF) membrane using a Mini Trans-Blot Electrophoresis
Transfer Cell (Bio-Rad Laboratory, CA, USA). Non-specific bind-
ing of antibodies was prevented by incubating membranes in 1%
bovine serum albumin (BSA) in tris buffer saline tween (TBST:
10mM Tris-HCl, pH 7.6, 150mM NaCl, 0.05% Tween 20). The
blots were incubated overnight at room temperature (for pTH)
or at 4◦C (for pERK, PKA, PKC δ), with the following primary
antibodies: specific polyclonal PKA catalytic subunit antibody
(1:2000 dilution; sc-903, Santa Cruz Biotechnology, Santa Cruz,
CA, USA); polyclonal anti PKCδ (1:1000 dilution; p8333, Sigma
Chemical Co., ST Louis, MO, USA); monoclonal anti-pERK1/2
(1:1000 dilution; sc-7383, Santa Cruz Biotechnology, Santa
Cruz, CA), polyclonal anti-pSer31 TH (1:250 dilution; AB5423,
Chemicon International, CA, USA), in TBST with BSA. After
extensive washings with TBST, the membranes were incubated
for 1 h, at room temperature, with peroxidase-labeled secondary
antibodies (anti-rabbit sc-2004 for PKA, PKCδ, pTH, total-ERK,
Santa Cruz; anti-mouse sc-2005 for phospho-ERK1/2, Santa
Cruz) both at 1:5000 dilution. After washing, immunoreactivity
was detected with an enhanced chemiluminescence western blot
detection system (ECL, Amersham-Pharmacia-Biotechnology,
Madrid, Spain) and visualized by Amersham Hyperfilm-ECL.
Quantification of PKA (42 kDA), PKCδ (78 kDA), phospho-
ERK1/2 (42 and 44 kDA) and TH phosphorylated at Ser31
FIGURE 3 | Western blotting analysis of phospho (p)-ERK1 and
phospho (p)-ERK2 immunoreactivity levels in the right ventricle
60min after saline (s) or naloxone (nx) administration to placebo
(Pl)- or morphine (Mor)-treated rats receiving vehicle (veh),
HA1004 (HA) or calphostin (Ca). The immunoreactivity corresponding
to ERK1 or ERK2 is expressed as a percentage respect to the
control group (Pl+veh+saline; defined as 100% value). Data are the
mean ± s.e.m. (n = 4–6). ∗p < 0.05, ∗∗p < 0.01 vs. the morphine
dependent group receiving saline instead of naloxone; +p < 0.05,
++p < 0.01 vs. the group pretreated with placebo instead of
morphine injected with naloxone; &p < 0.05, &&p < 0.01 vs. the group
receiving vehicle instead of HA. Right panels: representative bands
from autoradiograms at the known apparent molecular weight for
p-ERK1 or p-ERK2.
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(60 kDA) bands was carried out by densitometry (AlphaImager,
Nucliber, Madrid, Spain). The integrated optical density of bands
was normalized to the background values. The optical density
of the bands was normalized as a percentage of average of con-
trol. Relative variations between bands of experimental samples
and control samples were calculated in the same image. We
used β-actin or total-ERK as our loading control for all the
experiments. Before reprobing, blots were stripped by incuba-
tion with stripping buffer (glycine 25mM and SDS 1%) pH2, for
1 h at 37◦C. Blots were subsequently reblocked and probed with
1:1000 anti-β actin (Cell Signaling, 43 kDA) or anti-total ERK
(sc-154, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
ratio of PKA/β-actin, PKCδ/β-actin, phospho-ERK1/total ERK,
phospho-ERK2/total ERK and phosphoTH/β-actin was plotted
and analyzed.
HEMODYNAMIC PARAMETERS
The rats were anesthetized with thiopental sodium (40mg/kg,
i.p.), intubated and placed on a heated table to maintain
body temperature at 37◦C. A polyethylene cannula (PE-50)
was placed in the right femoral artery to measure blood pres-
sure and heart rate (HR). Catheters were connected to pressure
transducers (L969-A07 Abbott Ireland, Sligo, Ireland), moni-
tored on a PowerLab8/30 (ADInstruments, Pty Ltd., Oxford, UK)
and analyzed with LabChart software (ADInstruments, Pty Ltd.,
Oxford, UK). Naloxone (2mg/kg) was injected subcutaneously
after a 30min stabilization period and its effect on mean arterial
blood pressure (MAP) and HR was evaluated in rats implanted
with placebo or morphine concomitantly treated with vehicle or
HA-1004.
IMMUNOHISTOCHEMISTRY
Rats were killed with an overdose of pentobarbital (100mg/kg,
i.p.) for phospho-ERK1/2 determination 90min after naloxone
or saline administration. Following anaesthesia, rats were per-
fused through the descending aorta with 300ml of PBS (pH
7.4) followed by 500ml of cold, 4% paraformaldehyde in PBS.
Following perfusion, hearts were removed, postfixed in the same
fixative and stored at 4◦C overnight. The samples were then pro-
cessed routinely and embedded in paraffin wax. The sections
(5mm thick) were obtained on a microtome (HM310, Microm,
Barcelona, Spain) and were immunostained. The sections were
deparaffinised in xylene and dehydrated in a graded ethanol
series. Endogenous peroxidase activity was destroyed by 30min
FIGURE 4 | Western blotting analysis of phospho (p)-ERK1 and phospho
(p)-ERK2 immunoreactivity levels in the left ventricle 60min after saline
(s) or naloxone (nx) administration to placebo (Pl)- or morphine
(Mor)-treated rats receiving vehicle (veh), HA1004 (HA) or calphostin
(Ca). The immunoreactivity corresponding to ERK1 or ERK2 is expressed as a
percentage respect to the control group (Pl+veh+saline; defined as 100%
value). Data are the mean ± s.e.m. (n = 4–6). ∗∗p < 0.01 vs. the morphine
dependent group receiving saline instead of naloxone; ++p < 0.01 vs. the
group pre-treated with placebo instead of morphine injected with naloxone;
&&&p < 0.001 vs. the group receiving vehicle instead of HA. Right panels:
representative bands from autoradiograms at the known apparent molecular
weight for p-ERK1 or p-ERK2.
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treatment with 0.3% hydrogen peroxide in PBS. Sections were
washed in three 5min intervals of PBS and treated with NSS-
PBS (PBS containing 1% normal swine serum; Dako, Glostrup,
Denmark; and 0.5 Triton X-100) for 30min. Anti-phospho-
ERK1/2 antibody (diluted 1:1500 in NSS-PBS, overnight) was
used as a primary antibody and horse antimouse IgG (1:400,
1 h; Vector) as a secondary antibody. The bound primary anti-
body was localized by biotinylated secondary anti-rabbit IgG
(diluted 1:200 in NSS-PBS; Vector, Burlingame, CA, USA) and
subsequently with the avidin–biotin complex (ABC kits; Vector)
at room temperature for 1 h each. Visualization of antigen-
antibody reaction sites used 0.033% 30, 30-diaminobenzidine
(DAB; Sigma) and 0.014% H2O2 in 0.05M Tris-HCl buffer for
7min. The reaction was stopped in PBS and slides were cover-
slipped with DPX.
DRUGS AND CHEMICALS
Pellets of morphine base (Alcaliber Laboratories, Madrid, Spain)
or lactose were prepared by the Department of Pharmacy
and Pharmaceutic Technology (School of Pharmacy, Granada,
Spain); sodium dodecylsulphate, polyacrylamide gel and PVDF
membranes were obtained from Bio-Rad Laboratory (Teknovas,
Bilbao, Spain). Naloxone HCl and western blot reagents were
purchased from Sigma Chemical Co. (St Louis, MO, USA).
Naloxone HCl was dissolved in sterile 0.9% NaCl (saline)
and administered in volumes of 0.1mL/100 g body weight.
HA-1004 [N(-2′ guanidinoethyl-5-isoquinolinesulfonamide)]
was purchased from Sigma Chemical Co. and dissolved
in Milli-Q (Millipore, Bedford, MA, USA) sterile water.
Calphostin C (2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-
dihydroxy-2,6,7,11-tetrametoxy-3,10-dioxo-1-perylenyl)-1menth
ylethyl carbonic acid 4-hydroxyphenyl ester) was purchased from
RBI (Natick, MA, USA). The chronic delivery of HA-1004 or
Calphostin C was achieved by means of Alzet 2001 osmotic
minipumps (Alza, Palo Alto, CA), which deliver at 1μL/h.
SL327 alpha-[Amino-(4-aminophenylthio)methylene]-2-
(trifluoromethyl) benzeneacetonitrile was purchased from
Ascent, Scientific, Bristol, UK.
STATISTICAL ANALYSIS
The results are expressed as the mean ± s.e.m. Data were ana-
lyzed by One Way analysis of variance (ANOVA) followed by
FIGURE 5 | Western blotting analysis of phospho (p)-ERK1 and phospho
(p)-ERK2 immunoreactivity levels in the right ventricle 90min after
saline (s) or naloxone (nx) administration to placebo (Pl)- or morphine
(Mor)-treated rats receiving vehicle (veh), HA1004 (HA) or calphostin
(Ca). The immunoreactivity corresponding to ERK1 or ERK2 is expressed as a
percentage respect to the control group (Pl+veh+saline; defined as 100%
value). Data are the mean ± s.e.m. (n = 4–6). ∗p < 0.05, ∗∗p < 0.01 vs. the
dependent group receiving saline instead of naloxone; +p < 0.05 vs. the
group pretreated with placebo instead of morphine injected with naloxone;
&p < 0.05, &&p < 0.01 vs. the group receiving vehicle instead of HA. Right
panels: representative bands from autoradiograms at the known apparent
molecular weight for p-ERK1 or p-ERK2.
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the Newman–Keuls post-hoc test. Body weight gain and loss in
naïve- and morphine-dependent rats was analyzed by unpaired
Student’s t-test. One Way ANOVA followed by Dunett’s multiple
comparison test was used when required. Differences with a p
value less than 0.05 were considered significant.
RESULTS
Before performing the experiments, we assessed the efficacy of
chronic treatment with morphine by pellets implantation, which
has been previously shown to induce tolerance and dependence
to the effects of morphine (González-Cuello et al., 2004).
CHANGES IN BODY WEIGHT
The weight of the animals was recorded since the day of pel-
lets implantation until the day of sacrifice (day 8), before
receiving any injection. Rats treated with morphine showed
a significantly lower body weight gain than animals receiving
placebo pellets (Figure 1A). Chronic morphine-treated animals
showed a significant weight loss 60 after naloxone injection
when compared with placebo-pelleted group also receiving nalox-
one (Figure 1B). The injection of naloxone in rats chronically
treated with HA-1004, Calphostin C or SL327 concomitantly
with morphine induced a weight loss, similar to the group
chronically pretreated with vehicle plus morphine (Figure 1C).
Morphine-withdrawn animals treated with vehicle, HA-1004, cal-
fostin C or SL327 displayed characteristic abstinence symptoms:
Wet-dog shakes, teeth chattering, ptosis, tremor, piloerection,
lacrimation, rhinorrhea, chromodacryorrhea and spontaneous
jumping.
PKA AND PKC δ EXPRESSION IN THE RIGHT VENTRICLE
In this study, we have evaluated PKA or PKC δ levels in the right
ventricle blocking PKA activity using HA-1004 or SL327 or the
inhibition of PKC δ by calphostin C. As shown in Figure 2A,
chronic pre-treatment with HA-1004 concomitantly with mor-
phine antagonized the expression of PKA in both controls and
morphine-withdrawn animals. However, the administration of
SL327 did not inhibit the increase in PKA expression observed
FIGURE 6 | Western blotting analysis of phospho (p)-ERK1 and
phospho (p)-ERK2 immunoreactivity levels in the left ventricle
90min after saline (s) or naloxone (nx) administration to placebo
(Pl)- or morphine (Mor)-treated rats receiving vehicle (veh), HA1004
(HA) or calphostin (Ca). The immunoreactivity corresponding to ERK1
or ERK2 is expressed as a percentage respect to the control group
(Pl+veh+saline; defined as 100% value). Data are the mean ± s.e.m.
(n = 4–6). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the morphine
dependent group receiving saline instead of naloxone; +p < 0.05,
++p < 0.01, +++p < 0.001 vs. the group pre-treated with placebo
instead of morphine injected with naloxone; &p < 0.05, &&&p < 0.001 vs.
the group receiving vehicle instead of HA. Right panels: representative
bands from autoradiograms at the known apparent molecular weight for
p-ERK1 or p-ERK2.
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after naloxone administration to morphine-dependent animals
(Figure 2C). Regarding calphostin C, this inhibitor blocked the
expression of PKC δ observed after naloxone-induced withdrawal
in both control and morphine-dependent animals (Figure 2B).
Similar results were obtained in the left ventricle. These experi-
ments demonstrated that the doses of HA-1004 and calphostin
C used in this study are useful to inhibit the expression of PKA
or PKC δ, one of the main PKC isoforms involved in the adap-
tive changes observed in the heart during morphine withdrawal
(Cerezo et al., 2005).
EFFECTS OF HA-1004 AND CALPHOSTIN C ON ERK PHOSPHORYLATION
IN THE HEART
Once, we have established the ability of HA-1004 and Calphostin
C to antagonize the expression of PKA and PKC observed dur-
ing morphine withdrawal, then we determined if the increase
of PKA or PKC activity was responsible and related with the
increase of ERK phosphorylation showed in withdrawn rats. For
this purpose, the selective PKA inhibitor HA-1004 or the PKC
inhibitor Calphostin C were co-administered with morphine. At
different time point, chronic treatment with HA-1004, concomi-
tantly with morphine, antagonized the increase in the ERK1/2
phosphorylation observed during morphine withdrawal in the
right (Figures 3, 5) and left ventricle (Figures 4, 6). Calphostin
C did not prevent the increase in ERK1/2 observed in the right
ventricle or left ventricle 60 (Figures 3, 4) or 90min (Figures 5, 6)
after the injection of naloxone tomorphine-dependent rats. These
results suggest a crosstalk between PKA, but not PKC, and ERK
pathways.
EFFECTS OF SL327 OR HA-1004 ON TH PHOSPHORYLATION AT Ser31
As previously described, TH phosphorylation at Ser31 is depen-
dent on extracellular signal-regulated protein kinases 1 and 2
(Haycock et al., 1992). Therefore, we analyzed phospho-Ser31-
TH levels in the right and left ventricle after inhibition of ERK by
SL327, a drug that prevents the activation of ERK by inhibiting
MEK, the upstream kinase of ERK (Atkins et al., 1998). Firstly, we
determined the basal levels of phosphorylated (activated) ERK1/2
in the right and left ventricle from control and from morphine
withdrawn rats pre-treated with SL327. As shown in Figure 7,
phosphorylation of ERK1/2 was significantly decreased in the
presence of SL327 in both controls andmorphine-withdrawn ani-
mals. As SL327 effectively reduced basal levels of phospho-ERK
1/2 inmunoreactivity, we injected SL327 in control rats and in
FIGURE 7 | Inmunoblots of ERK1/2 in the right and left ventricles
isolated from placebo (pla,p)- or morphine (mor, m)-dependent rats
after subcutaneous administration of naloxone (n) in rats treated with
SL327 (SL, 100mg/kg, i.p.) or vehicle (veh, v), 1 h before naloxone
injection. Phospho (p)ERK1 and pERK2 immunoreactive bands were
measured, normalized to the background values, and expressed as
percentages of controls. Data correspond to mean ± s.e.m. (n = 4).
∗∗∗p < 0.001 vs. its control group. Bottom panels: representative bands
from autoradiograms at the known apparent molecular weight for p-ERK1
or p-ERK2.
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animals made dependent onmorphine, 1 h before saline or nalox-
one and determined phospho-Ser31 TH in the right and left
ventricle 90min after the administration of the opioid antagonist.
As shown in Figures 8A,B, phospho Ser31 TH levels decreased
in the right and left ventricle of morphine-dependent rats injected
with SL327 before naloxone, when compared to morphine-
dependent rats treated with vehicle instead of SL327. As
mentioned above, SL327 effectively reduces basal levels of
phospho-ERK1/2 inmunoreactivity, thereby suggesting that the
decrease in phosphoSer31 TH levels after treatment with SL327
is not caused by a non-specific action of the compound on MEK.
Thus, these results suggest that TH phosphorylation at Ser31
following morphine withdrawal occurs downstream of ERK.
According to a previous study (Almela et al., 2008), 60min
after naloxone-precipitated morphine withdrawal, there were not
changes in the levels of phospho-Ser31 TH (data not shown).
However, rats chronically treated withmorphine and given nalox-
one showed significant increases in phospho-Ser31 TH in the
right and left ventricle 90min after the opioid antagonist injec-
tion compared with the corresponding control group receiving
naloxone and with the morphine dependent animals receiving
saline (Figures 8C,D). To assess the contribution of PKA to the
regulation of TH, we have examined TH phosphorylation at
Ser31 duringmorphine withdrawal in animals receiving the selec-
tive inhibitor of PKA, HA-1004. Chronic infusion of HA-1004
completely blocked the ability of naloxone-precipitatedmorphine
withdrawal to increase the levels of phospho-Ser31 TH in the
right and left ventricle (Figures 8C,D). Since SL327 failed to
inhibit PKA expression in the right and left ventricle, these results
demonstrated that PKA activity is required for ERK-mediated TH
phosphorylation at Ser31 after morphine withdrawal.
CARDIOVASCULAR EFFECTS OF NALOXONE-PRECIPITATED MORPHINE
WITHDRAWAL
As shown in Figures 9A,B, the pre-treatment with HA instead
of vehicle did not induce significant changes in MAP. However,
basal MAP was significant decreased in rats treated chronically
with morphine comparing placebo group (Figure 9A). In addi-
tion, the injection of naloxone (2mg/kg s.c.) in placebo+vehicle-
or placebo+HA1004-treated rats evoked no significant changes in
MAP. However, naloxone administration tomorphine-dependent
rats induced an immediate and significant increase in MAP
(2–8min) vs. placebo+vehicle rats injected with naloxone
(Figure 9B). Similarly, the injection of naloxone in rats chron-
ically treated with HA-1004 concomitantly with morphine
induced significant changes in the MAP when compared with
the morphine-dependent groups treated with vehicle instead of
HA-1004 (Figure 9B).
The morphine chronic treatment also decreased the basal
HR vs. placebo treatment. The rats pre-treated with placebo
FIGURE 8 | Western blotting analysis of tyrosine hydroxylase (TH)
phospho (p) Ser31 in the right ventricle and left ventricle 90min after
saline (s) or naloxone (n, nx) administration to placebo (p, Pl)- or
morphine (m, Mor)-treated rats receiving vehicle (v, veh) or SL327 (SL)
(A,B), veh or HA-1004 (HA) (C,D).The immunoreactivity corresponding to TH
phospho-Ser31 is expressed respect to the control group (p+v+n or
Pl+veh+saline; defined as 100% value). Data are the mean ± s.e.m.
(n = 4–6). ∗p < 0.05 vs. the morphine dependent group receiving saline
instead of naloxone; +p < 0.05, ++p < 0.01 vs. the group pre-treated with
placebo instead of morphine injected with naloxone; &&p < 0.001 vs. the
group receiving vehicle instead of HA; #p < 0.05, ##p < 0.01 vs. the
dependent group injected with SL327. Bottom panels: representative bands
from autoradiograms at the known apparent molecular weight for TH
phosphorylated at Ser31.
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FIGURE 9 | Baseline mean arterial blood pressure (MAP, mmHg) in rats
implanted with morphine (mor) or placebo (pla) pellets concomitantly
with vehicle (veh) or HA-1004 (HA), just before naloxone injection (A).
Effects of naloxone (2mg/kg, s.c.) on changes in MAP, in rats pretreated with
mor or pla concomitantly with veh or HA. Naloxone (nx) was injected at time 0
(B). Data are the mean ± s.e.m. (n = 4–6). ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 vs. pla+veh; ++p < 0.01, +++p < 0.001 vs. pla+HA.
pellets did not show changes in HR (Figure 10A). However, 5min
after naloxone injection, we found a significant enhancement of
HR in rats treated chronically with morphine. The top peak-
time effect was 10min later naloxone injection although HR
remained elevated for 120min in themorphine dependent groups
(Figure 10B).
LOCALIZATION OF PHOSPHO-ERK1/2 BY IMMUNOHISTOCHEMISTRY
To obtain more information concerning the cellular localization
of the phospho-ERKs in the heart, we studied the distribution
of these proteins by immunohistochemical procedures using the
same phospho-ERK1/2 antibody. Rats were sacrificed 90min
after saline or naloxone injection. As shown in Figure 11, high
levels of phospho-ERK immunoreactivity were observed in
the right and left ventricle after naloxone administration to
morphine-dependent rats. The immunolabeling was mainly
present in cytoplasmic compartments, suggesting a local acti-
vation of the protein. A nuclear staining was also observed in
some myocytes, supporting the idea of a possible translocation
of activated ERK proteins into the nucleus. By contrast, there
was no staining in the right and left ventricle from control rats
given naloxone or dependent rats injected with saline. These
immunohistochemistry results are consistent with western blot
analysis showed in the present study.
DISCUSSION
Our results demonstrated: (i) Morphine withdrawal activates
ERK1/2 and phosphorylated tyrosine hydroxylase (TH) at
Ser31 in the right and left ventricle; (ii) HA-1004 blocks the
FIGURE 10 | Baseline heart rate (HR, beats per minute, bpm) in rats with
morphine (mor) or placebo (pla) pellets implantation concomitantly
with vehicle (veh) or HA-1004 (HA), just before naloxone injection (A).
Changes in HR 20min after naloxone (2mg/kg, s.c.) injection, in rats
pre-treated with mor or pla concomitantly with veh or HA (B). Data are the
mean ± s.e.m. (n = 4–6). ∗p < 0.05, ∗∗∗p < 0.001 vs. pla+veh; ++p < 0.01,
+++p < 0.001 vs. pla+HA.
phosphorylation of ERK 1/2 and TH; and (iii) chronic morphine
treatment decreases baseline cardiovascular parameters (MAP
and HR). According to our finding, previous studies demon-
strated that chronic μ-opiod receptor stimulation decreases mus-
cle sympathetic nerve activity (Kienbaum et al., 2001, 2002), NA
plasma concentration (Kienbaum et al., 2001), and dopamine
turnover in the heart (Rabadán et al., 1997) and attenuates both
contractile dysfunction and development of myocardial infarc-
tion (Gross et al., 2007; Peart et al., 2008). However, μ-opioid
receptor blockade by naloxone in patients with chronic opioid
abuse or in morphine dependent rats unmasks these effects,
resulting in markedly increased muscle sympathetic nerve activ-
ity, NA plasma concentrations (Kienbaum et al., 2001; Peart and
Gross, 2006), NA and dopamine turnover (Pugsley, 2002; Almela
et al., 2008), total TH expression (Almela et al., 2008) and an
increase in MAP and HR (Almela et al., 2011; Shanazari et al.,
2011), two objective and accurate measurable signs of opioid
withdrawal in man. Altogether, these results suggest that an up-
regulation of TH would facilitate the capacity of noradrenergic
neurons to synthesize NA, which could contribute to the increase
in NA turnover and in the hemodynamic changes observed in the
heart during morphine dependence.
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FIGURE 11 | Morphine withdrawal activates ERK1/2 in the right and
left ventricle. Rats were rendered dependent on morphine during 7
days and, on day 8, were injected with saline or naloxone
(subcutaneously). Controls groups received placebo pellets at the same
time schedule and on day 8 were given with saline or naloxone. 90min after
injections, rats were perfused and the right and left ventricle were
processed for phospho (p)ERK1/2 immunohistochemistry. Photographs
show the immunohistochemical detection of pERK1/2 in the left ventricular
wall (A–C). These results are representative of four independent
experiments. Normaski interference optics. Scale bar 30mm (A), 20mm
(B,C). ERK, extracellular signal regulated kinase.
Previous results from our laboratory demonstrated the capa-
bility of the selective PKA inhibitor HA-1004 for attenuating the
increase of NA turnover, the total TH levels (Almela et al., 2007b)
and the phosphorylation of TH (Almela et al., 2008) in morphine
treated rats. However, present results show that HA-1004 failed
to affect significantly MAP or HR during withdrawal. Because
the cardiovascular response induced bymorphine withdrawal was
not altered by the PKA inhibitor, dissociation could be made
between the physiological and cellular/molecular responses to
naloxone-precipitated morphine withdrawal. Hence, the data of
the present study suggest that the cardiovascular response and the
biochemical changes which occur during morphine withdrawal
could be mediated by different pathways and mechanisms.
Many pathways involved in morphine dependence are subject
to feedback mechanisms that can either amplify or suppress their
own signaling and there is considerable signaling from one path-
way to another, a phenomenon known as crosstalk. Consequently,
cell organized responses to get adapt to specific environmental
conditions are the result of the sum of the intensity and dura-
tion of signals from several pathways and how they interact with
each other. Since there is no evidence that PKA activation is
required for stimulation of MAPK induced by morphine with-
drawal in the heart (Almela et al., 2007a), this study evaluates the
crosstalk between cAMP/PKA and ERKs and subsequently phos-
phorylation of TH at Ser31 in morphine-dependent rats. These
two ancient and conserved signaling pathways are involved in
many brain disorders, including drug addiction (Ren et al., 2004).
Although several signaling pathways can mediate activity-
dependent phosphorylation of TH, the only PK reported to
phosphorylate TH at Ser31 in vitrowas ERK (Haycock et al., 1992;
Lindgren et al., 2002). In situ phosphorylation of TH at Ser31
increases TH activity and catecholamine synthesis (Dunkley et al.,
2004). Given that TH is phosphorylated on a specific serine
residue (Ser31) by ERK, it is possible that activation of ERK1/2
in the heart provides a way in which TH is regulated under mor-
phine dependence. In agreement with previous studies (Almela
et al., 2008), we found that treatment with 100mg/kg of SL327, a
dose that selectively blocks MEK (Atkins et al., 1998; Pozzi et al.,
2003), decreased the morphine withdrawal stimulation of Ser31
phosphorylation in the right and left ventricle. These data suggest
that morphine withdrawal induced an activation of ERKs, which
resulted in enhancement of TH phosphorylation at Ser31.
According to previous results from our laboratory obtaining
by western blot and inmunohistochemistry (Almela et al., 2007a),
present data shows that naloxone- induced morphine withdrawal
increases phosphorylated ERK1/2 in the heart, indicating that this
treatment enhances ERKs activity. In the present study, we uti-
lized the PKA or the PKC inhibitor to check the involvement of
these pathways in the activation of ERKs during morphine with-
drawal. Present results demonstrate that HA-1004 antagonized
the increase in ERK1/2 observed during morphine withdrawal.
These data indicate that PKA signaling pathway modulates the
increased levels of ERK1/2 observed during morphine withdrawal
and suggest a crosstalk between PKA and ERK in the heart that
couldmediate the adaptive changes observed after naloxone injec-
tion to morphine dependent rats. However, the activation of
ERK1/2 observed in the present study is independent of PKC
pathway. According to this result, it has been indicated that there
is no direct interaction between PKC and MAPK pathways medi-
ating the effect of endothelin-1 on Glut1 transcription (Kao and
Fong, 2008).
Although the mechanism of crosstalk between PKA and ERK
pathways has not yet been clarified, it is possible that PKA
pathway facilitates MEK1/2 which activates the ERK1/2 pathway
(Stork and Schmitt, 2002; Obama et al., 2007). The activated
ERK pathway increases the phosphorylation of proteins related
to morphine dependence, including TH.
Targeting phosphorylated TH at Ser31 using specific antibod-
ies, in the present study we have shown that HA-1004 blocked the
increase in the level of TH phosphorylation at Ser31 induced after
naloxone injection to morphine dependent rats in the right and
left ventricle. These data suggest that crosstalk between PKA and
ERK pathways is a key mediator design necessary to regulate the
Ser31 phosphorylation of TH. In conclusion, our results indicate
that TH phosphorylation at Ser 31 is regulated by ERK and PKA
pathways through crosstalk mechanisms.
It has been described that tyrosine kinase receptor can use
proximal located G-protein/GPCR signaling components in an
integrated manner to induce activation of key regulatory path-
ways linked to different cellular processes (see Waters et al., 2004
for review).
It is clear from this study that PKA is implicated in the ERK
activation; the activated ERK pathway increases the phosphoryla-
tion of proteins related to morphine dependence, including TH.
Our data suggest that cross-talk between PKA and ERK pathways
is a key regulatory design necessary to regulate the phosphory-
lation of TH. These findings should improve our understanding
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of the mechanisms involved in the cardiac adaptive changes
observed during morphine withdrawal. In addition, present find-
ing suggest that the activation of TH could be a factor that
would contribute to cardiovascular alteration, such as arrhyth-
mias, observed in heroin addicts (Nerantzis et al., 2011) and could
be useful for future treatment strategies focused on addictive
processes.
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